Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"U.S. Army Medical Research Acquisition Activity","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injury","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"PUERTO RICO","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"IACTA Pharmaceuticals"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              IACTA Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Puerto Rico
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injury

              Details:

              The award will be used for the development and preclinical studies of IC 800, a novel therapy for the topical treatment of ocular pain, utilizing the body’s endogenous pain controllers, the enkephalins.

              Lead Product(s): IC 800

              Therapeutic Area: Ophthalmology Product Name: IC 800

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: U.S. Army Medical Research Acquisition Activity

              Deal Size: $1.0 million Upfront Cash: Undisclosed

              Deal Type: Funding October 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY